These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 16175357)

  • 21. Lessons Learned From a Randomized Study of Oral Valganciclovir Versus Parenteral Ganciclovir Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR Trial.
    Åsberg A; Humar A; Rollag H; Jardine AG; Kumar D; Aukrust P; Ueland T; Bignamini AA; Hartmann A
    Clin Infect Dis; 2016 May; 62(9):1154-60. PubMed ID: 26908810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.
    Asberg A; Rollag H; Hartmann A
    Expert Opin Pharmacother; 2010 May; 11(7):1159-66. PubMed ID: 20367273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
    Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
    Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir.
    Fellay J; Venetz JP; Aubert JD; Seydoux C; Pascual M; Meylan PR
    Transplant Proc; 2005 Mar; 37(2):949-51. PubMed ID: 15848585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.
    Battiwalla M; Paplham P; Almyroudis NG; McCarthy A; Abdelhalim A; Elefante A; Smith P; Becker J; McCarthy PL; Segal BH
    Transpl Infect Dis; 2007 Mar; 9(1):28-32. PubMed ID: 17313468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of cytomegalovirus infection after renal transplantation: experience from a single center in China.
    Li Y; Yan H; Xue WJ; Tian PX; Ding XM; Pan XM; Feng XS; Xiang HL; Hou J; Tian XH; Zheng J; Ding CG; Fan P; Liu HB
    Ann Transplant; 2013 Mar; 18():125-35. PubMed ID: 23792512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.
    Ciszek M; Mucha K; Foroncewicz B; Chmura A; Pączek L
    Ann Transplant; 2014 Jan; 19():60-3. PubMed ID: 24481271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.
    Varga M; Remport A; Hídvégi M; Péter A; Kóbori L; Telkes G; Fazakas J; Gerlei Z; Sárváry E; Sulyok B; Járay J
    Transpl Infect Dis; 2005 Jun; 7(2):63-7. PubMed ID: 16150092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytomegalovirus (CMV) glycoprotein B genotypes and response to antiviral therapy, in solid-organ-transplant recipients with CMV disease.
    Humar A; Kumar D; Gilbert C; Boivin G
    J Infect Dis; 2003 Aug; 188(4):581-4. PubMed ID: 12898447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
    Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late primary cytomegalovirus infection presenting with acute inflammatory demyelinating polyneuropathy in a heart transplant recipient: a case report and review of the literature.
    Hodowanec AC; Simon DM
    Transpl Infect Dis; 2012 Oct; 14(5):E116-20. PubMed ID: 22938143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
    Torres-Madriz G; Boucher HW
    Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients.
    Gagermeier JP; Rusinak JD; Lurain NS; Alex CG; Dilling DF; Wigfield CH; Love RB
    Transpl Infect Dis; 2014 Dec; 16(6):941-50. PubMed ID: 25491023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy.
    Gilbert C; LeBlanc MH; Boivin G
    Herpes; 2001 Nov; 8(3):80-2. PubMed ID: 11867025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
    San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
    Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cytomegalovirus infection in transplant recipients].
    Gondo H
    Nihon Rinsho; 1998 Jan; 56(1):173-8. PubMed ID: 9465685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The CARI guidelines. CMV disease and kidney transplant: treatment of cytomegalovirus disease in renal transplant recipients.
    Caring for Australians with Renal Impairment (CARI)
    Nephrology (Carlton); 2004 Oct; 9 Suppl 3():S37-40. PubMed ID: 15469554
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T; Lai WK; Mutimer D
    Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient.
    Pfau P; Kochman ML; Furth EE; Lichtenstein GR
    Am J Gastroenterol; 2001 Mar; 96(3):895-9. PubMed ID: 11280572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.